Loading organizations...
§ Public · Cambridge, MA, USA
Clinical-stage biotechnology company developing VDCs for ocular and urologic cancers, including choroidal melanoma.
Aura Biosciences is a Boston, Massachusetts-based clinical-stage biotechnology company developing targeted oncology therapies known as virus-like drug conjugates to treat solid tumors. The pre-revenue firm focuses primarily on creating treatments for ocular and urologic cancers, with its lead product candidate, bel-sar, currently undergoing global Phase 3 clinical trials for early-stage choroidal melanoma and non-muscle invasive bladder cancer. Operating as a publicly traded entity on the NASDAQ exchange under the ticker symbol AURA, the enterprise employs approximately 100 people and raised roughly $115 million during its initial public offering in October 2021. Prior to entering the public equity markets, the biotechnology business received venture capital backing from prominent institutional investors including Matrix Capital Management, Medicxi, Advent Life Sciences, and Ysios Capital. Aura Biosciences was officially established in 2009 by founder Elisabet de los Pinos.
Aura Biosciences has raised $266.2M across 8 funding rounds.
Aura Biosciences has raised $266.2M in total across 8 funding rounds.
Aura Biosciences has raised $266.2M across 8 funding rounds. Most recently, it raised $80.0M Other Equity in March 2021.
Aura Biosciences has raised $266.2M in total across 8 funding rounds.
Aura Biosciences's investors include Karan Takhar, Surveyor Capital, Adage Capital Management, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfond Ventures, Medicxi, Rock Springs Capital, Velosity Capital, Joel Jean Mairet.
Aura Biosciences is a clinical-stage biotechnology company developing precision therapies for solid tumors using its proprietary virus-like drug conjugate (VDC) platform, focusing on high unmet needs in ocular and urologic cancers.[1][2][3][7] Its lead product, belzupacap sarotalocan (bel-sar or AU-011), targets early-stage choroidal melanoma in a global Phase 3 CoMpass trial under FDA Special Protocol Assessment, with additional exploration in choroidal metastases, ocular surface cancers, and non-muscle invasive bladder cancer (NMIBC).[3][9] The company serves oncology patients needing organ-preserving treatments, addressing limited options in these rare cancers affecting over 60,000 annually in the US and Europe, and shows growth momentum as a publicly listed entity (NASDAQ: AURA) with ongoing late-stage trials, orphan drug designations, and recent patent filings.[1][3]
Aura Biosciences emerged from innovative research into virus-like particle-drug conjugates (VDC) to tackle underserved oncology areas, with early investment from Advent Life Sciences in its 2015 Series B round led by CEO Elisabet de los Pinos.[1] The company advanced its pipeline rapidly, dosing the first patient in a Phase 2 suprachoroidal study for choroidal melanoma and presenting Phase 1b/2 data at key conferences like the Macula Society and AAO meetings.[5][6] Pivotal moments include interim Phase 2 data in 2022 showing efficacy in early-stage choroidal melanoma, preclinical support for choroidal metastasis at ARVO 2022, and progression to Phase 3 CoMpass trial design announcement, marking its evolution into a late-stage biotech headquartered in Boston.[1][3]
Aura Biosciences rides the wave of targeted oncology therapies and precision medicine, particularly in rare solid tumors where surgery or radiation risks vision loss or organ damage, aligning with trends in immune-ablative and virus-based conjugates.[7][8] Timing is ideal amid rising focus on ocular oncology (e.g., choroidal melanoma's poor prognosis without effective non-invasive options) and urologic cancers like NMIBC, bolstered by regulatory fast tracks and a market need for >60,000 annual cases.[3] Favorable forces include biotech investor interest in platform technologies with multi-indication potential and advancements in suprachoroidal delivery for eye diseases; Aura influences the ecosystem by pioneering VDC for organ-sparing treatments, potentially setting standards for similar rare cancers.[1][2][9]
Aura's path forward centers on CoMpass Phase 3 topline data, potential regulatory filings for bel-sar in choroidal melanoma, and Phase 1/2 expansion in NMIBC and other ocular indications, with new patents securing long-term IP.[3] Trends like AI-driven trial enrichment, combination immunotherapies, and global orphan drug incentives will shape its trajectory, positioning it to evolve from clinical-stage player to commercial oncology leader transforming patient outcomes in underserved areas. This builds on its VDC platform's promise as the first targeted therapy for ocular melanoma, delivering precision where it's needed most.[1][3][7]